New Virus-Based COVID booster enters human trials

NCT ID NCT05389319

Ongoing ⭐️ VACCINE ⭐️ Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new COVID-19 booster vaccine called Prime-2-CoV_Beta, made from a modified orf virus. It involves 96 healthy adults aged 18-55 who have already been vaccinated or infected. The main goal is to check safety and how well the vaccine boosts the immune system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prime-2-CoV_Beta (a vaccine made from a modified orf virus to boost immunity against COVID-19)
What this could lead to: If successful, this could provide a new type of COVID-19 booster that may offer broader or longer-lasting protection.
What could go wrong: This is an early, small trial (96 people) focused on safety and immune response, not on preventing infection. The vaccine may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Bernhard-Nocht-Institut für Tropenmedizin

Hamburg, Free and Hanseatic City of Hamburg, 20359, Germany
University Hospital Tübingen, Institute of Tropical Medicine

Tübingen, Baden-Wurttemberg, 72074, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.